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Previous studies from this and other laboratories have shown that the novel microtubule 
poison, JG-03-14, which binds to the colchicine binding site of tubulin, has the capacity 
to promote both autophagy and apoptosis in breast tumor cells, as well as interfering with 
endothelial cell function and potentially disrupting tumor vasculature. The current work 
was designed to investigate the interaction between JG-03-14 and cell culture models of 
colon carcinoma and melanoma, specifically HCT116 human colon carcinoma cells and 
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B16F10 murine melanoma cells.  In both cases, JG-03-14 promoted death in the bulk of 
the treated population. FACS analysis, DAPI and TUNEL staining indicated that only a 
small fraction of the cell population was undergoing apoptosis; furthermore, there was no 
evidence of mitotic catastrophe (micronuclei in bi-nucleated cells). Staining with acridine 
orange and monodansylcadaverine as well as electron microscopy demonstrated the 
formation of autophagic vesicles, consistent with the cells undergoing extensive 
autophagy. Cell cycle analysis indicated that cells had arrested in the G2/M stage, with 
evidence of a hyperdiploid population. Residual surviving cells appeared to be in a state 
of senescence; furthermore, the senescent cells failed to recover proliferative capacity, 
indicating that the cells were reproductively dead.  Toxicity studies in cardiomyocytes 
with comparisons to combretastatin and taxol indicated that JG-03-14 was the less toxic 
of the microtubule poisons. In summary, our studies indicate that JG-03-14 induces 
autophagic and reproductive cell death in HCT116 colon carcinoma cells and B16F10 
murine melanoma cells with limited toxicity to the normal cells that are generally 
susceptible to taxol and combretastatin.  The possibility of alternative mode(s) of cell 
death (autophagy and irreversible senescence) induced by JG-03-14 makes it a potentially 
useful candidate as a chemotherapeutic drug that could be used to treat cancers resistant 
to apoptosis. The relative lack of toxicity of JG-03-14 provides additional support for its 
potential use in the treatment of malignancies.  
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CHAPTER 1 Introduction 
 
 
 
 
I. Cancer 
Cancer is the second leading cause of death worldwide and is expected to take 
about 1500 lives per day this year (American Cancer Society, 2010).  Two of the 
more prominent sub-classes of cancer are colorectal cancer, which is the third 
most prevalent cancer type, and melanoma. Colorectal cancer alone is projected 
to generate 143,570 cases this year and is estimated to account for 51,370 
deaths.  In 2009, there were more than a million new cases of skin 
cancer, including 68,720 cases of the most fatal form, malignant melanoma, with 
8,650 deaths associated with melanoma alone (American Cancer Society, 2009).  
For both of these cancers, if malignancies are detected early, the tumors 
can be removed surgically, and the diseases are relatively curable. In contrast, 
highly aggressive, metastatic lesions of colorectal cancer and melanoma are 
notoriously resistant to chemotherapy (Fojo et al., 2007; Gray-Schopfer et al., 
2007; Gomez et al, 2000), and in cases where these tumors are not detected and 
removed early in their progression, death is likely to result from the metastatic 
lesion.  
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The development of therapies for both metastatic diseases is moving 
forward quite slowly (Chin et al., 2006; Linos et al., 2009). Colorectal cancer is 
usually treated with therapies that include 5-fluorouracil, monoclonal antibodies, 
and inhibitors of EGFR and VEGF (Shia, 2008; Gallegos-Arreola et al, 2008; 
Zrieki et al, 2008; Schwartz 2008; Igbal and Lenz 2004).  Treatment options for 
late stage melanoma are quite limited and include immunotherapies such as 
Interleukin-2 and Interferon; however, these have been met with limited success 
overall (Bajetta et al, 2002).  Furthermore, the overall adverse effects of current 
treatment strategies are quite debilitating and patient side effects such as 
extreme flu-like symptoms and a host of organ toxicities which need to be closely 
monitored (Hancock et al, 2004).   In order to develop improved approaches for 
treating these diseases, it is important to identify novel compounds that will be 
effective at selectively targeting the tumor at pharmacological levels while 
circumventing common mechanisms of resistance such as decreased 
accumulation and drug inactivation in tumor cells, increased DNA repair and 
mutation of drug targets (Eastman and Schulte, 1988; Lai et al, 1988; Cazin et al, 
1992).    
II. Metastasis and Angiogenesis 
As with many cancers, malignant melanoma that has metastasized to distant 
sites is very difficult to treat and is rarely curable (Hancock et al, 2004; Delaunoit 
et al., 2005).  Melanoma is not only highly metastatic in nature but also is 
heterogeneous with regards to organ implantation (Kaplan et al., 2005).  The 
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lungs and liver are common organ sites for metastatic disease spread but all 
organs are susceptible and late relapses are not uncommon (Tsoa et al, 1997). 
 Similarly, colorectal cancer is highly metastatic and most commonly targets 
the liver. The distant organ lesions for colon cancers yield a 5-year survival rate 
of only 11% (American Cancer Society, 2010).   
The events that lead to the formation of these metastatic lesions may 
present novel and previously unexplored targets for chemotherapy.  It has been 
found that tumors release tumor specific paracrine and autocrine factors that can 
trigger bone marrow derived cells and hematopoetic progenitor cell release to 
alter the micro-environment where the metastatic lesion may implant (Kaplan et 
al, 2005).  In the case of melanoma, this pre-metastatic niche and implantation 
can occur in any organ, which makes the task of controlling the newly implanted 
tumors particularly difficult.  Cancer cells not only release factors for creating a 
pre-metastatic niche in distant organs, but also release factors from the bone 
marrow that will promote the recruitment of endothelial vessels for nutrient supply 
(Bergers et al, 2003).  One of the factors identified as being released by 
melanoma under hypoxic conditions is vascular endothelial growth factor 
(Shellman et al, 2003).  VEGF is involved with the angiogenic switch which 
occurs when the tumor is greater than 2 mm in diameter and no longer self 
sufficient and requires the recruitment and formation of micro-vessels to siphon 
nutrients from the host (Bergers et al, 2003).  Cell division and migration of 
endothelial cells for generating the tumor blood supply rely on microtubules for 
function.  This indicates that the subunits of microtubules could represent an 
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ideal target for tumoricidal and tumoristatic cancer chemotherapy, as well as 
targets for anti-angiogenic prevention of disease recurrence (Pasquier et al., 
2008).   
III. Microtubules as a Target for Chemotherapy 
The cytoskeleton plays a dynamic and intricate role in cell survival and 
proliferation (Nogales, 2001).  Microtubules are a major component of the 
cytoskeleton and function in transport, mitosis and cytokinesis.  In current cancer 
chemotherapy, a number of drugs target the microtubule subunits in order to 
effectively disrupt proliferation (Jordan et al, 1998).  The drug targets typically 
bind and sequester the tubulin units, promoting polymerization or bind the 
established microtubules and depolymerize them (Kuo et al., 2004). 
Polymerization of microtubules by taxanes and other natural compounds such as 
the epothilones can lead to arrest in the G2/M phase of the cell cycle followed by 
apoptosis (Balog et al, 1996; Xiao et al, 2005; Wagenknecht et al, 1998; Blajeski 
et al, 2001).   The microtubule depolymerizing poisons include the vinca alkaloids 
such as vincristine and vinblastine or the colchicine binding site agents 
combretastatin A-4, colchicine and 2-methoxyestradiol.  The end result of 
exposure of tumor cells to many of these drugs is effectively an apoptotic 
response through the induction of cell cycle arrest and effector caspase mediated 
killing (Moss et al., 2006).  However, there is growing recognition of other 
responses to microtubule poisons including autophagy, aberrant mitosis and 
senescence (Vicencio et al, 2008; Arthur et al 2007).  
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IV. Cell Cycle Effects 
Microtubule poisons that have been used as chemotherapeutic drugs act through 
microtubule polymerization or depolymerization; these poisons can also activate 
cell cycle checkpoints either during the G1 and S phases and/or during spindle 
assembly. Taxol and other microtubule polymerizers interfere with spindle 
dynamics and interfere with mitosis (Sudo et al, 2004; Desai, 1997).  This spindle 
disruption can lead to the activation of p53 (Amundson et al, 1998).  The role of 
p53 is complex; p53 will generally arrest cells in G1 through the cdk2-cyclin B 
inhibitor p21/WAF1/Cip1. There is also evidence that p53 can induce various cell 
killing pathways including autophagy and apoptosis (Levine et al, 2008; Shen et 
al, 2001). G1 arrest though is not always permanent and cells can escape the 
arrest, leading to chromosomal breakage in the subsequent G2 phase (Deckbar 
et al, 2010).  This subsequent chromosomal breakage and slippage may lead to 
genomic instability and facilitate the development of resistance (Gisselsson, 
2001). 
Microtubule polymerizers and depolymerizers have strikingly different 
effects on tubulin subunits but both effectively disrupt cell cycle transitions as 
cancer therapy (Blajeski et al 2002).  Depolymerizers similar to JG-03-14 have 
been shown to arrest the cell cycle in the G2/M phase, as opposed to the G1 
phase observed with many DNA damaging agents and radiation (Ivanov et al, 
2007; Zhai et al, 1996; DiLeonardo et al, 2001).   Along with the G2/M phase 
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arrest, some microtubule poisons, including JG-03-14, allow the cell to 
continually replicate DNA without cytokinesis.  This process is called 
endoreduplication (Moon et al, 2008).     
In our studies, we have observed that the G2/M arrest and subsequent 
generation of a hyperdiploid population is accompanied by autophagic cell death 
(Arthur et al, 2007).  JG-03-14’s ability to permanently arrest cells in later stages 
supports its potential use to promote cell killing and reproductive cell death. G1 
arrest, which is commonly short-term arrest, has the potential to produce 
resistant progeny through the cell re-entering the cell cycle and execution of 
mitosis (Gisselsson, 2001).  The absence of the necessity for apoptosis and 
possibly the absence of p53 mediated G1 arrest are two potential benefits of 
utilizing JG-03-14 as a microtubule de-polymerizering agent. 
V. Death Responses  
    A. Apoptosis 
The term apoptosis comes from the literal meaning of leaves falling from a tree.  
Apoptosis is an evolutionarily conserved process where cell death is executed 
through a family of cysteine-aspartic acid directed proteases knows as the 
caspase family (Mignotte et al, 1998).  In the death receptor extrinsic pathway 
and intrinsic pathways, the mitochondria release cytochrome c, which is critical to 
activate apoptotic factors such as Apaf-1 (Scoranno et al. 2003). Cytochrome-c is 
released from the mitochondria when Bcl-2 family proteins Bax and Bad 
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homodimerize and form a pore.  This pore provides an escape route by which 
mitochondrial cytochrome c can infiltrate the cytoplasm and form the apaf-1 
complex moiety.  This Apaf-1 moiety will then form a tetramer called an 
apoptosome that is capable of cleaving caspase-9 (Twiddy et al, 2007).  
Caspase-9 is an activator caspase that will cleave caspase-3, which 
subsequently results in cleavage of poly-ADP ribose polymerase and ultimately 
destruction of the cell.  Apoptotic cell death is characterized by membrane 
blebbing and the formation of apoptotic bodies, which is accompanied by 
fragmentation of the nucleus and DNA (Taylor et al, 2008).   
Although the apoptotic pathway has been well described, there is 
mounting evidence that other mechanisms of death may be involved in the 
response to cancer chemotherapy (Shao et al, 2004; Arthur et al, 2007). In many 
cases the induction of apoptosis is in response to DNA damage and ultimately 
leads to cell suicide dependent or independent of p53 (Gulbins et al, 2000). 
However, tumor cells are notorious for evading apoptotic death through the 
expression of anti-apoptotic proteins or other mutations (Weinberg, 2000).  One 
common mechanism for evasion of apoptosis is an increase in MDM2, a protein 
that degrades p53, mutations in p53 or downregulation of p53 (Zhou et al, 2003; 
Wattel et al, 1994). This is evidence that targeting other modes of cell death 
would potentially be a useful strategy for cancer chemotherapy.   
    B. Autophagy 
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There continues to be controversy in the scientific literature as to whether 
autophagy is a mode of cell killing or a mode of survival or both.  The term 
autophagy comes from the Greek definition meaning “self eating”.  The process 
is thought to have a multitude of purposes and is activated in response to 
hypoxic stress or nutrient deprivation (Azad et al, 2008).  Nutrient deprivation 
induced autophagy is thought to be under control of the PI3K-Akt-mTOR pathway 
(Ravikumar et al, 2004).  However, when nutrients are abundant in the presence 
of chemotherapeutics, the mechanism of autophagic induction is somewhat of an 
anomaly and yet to be fully described. Regardless, autophagy is initiated by the 
formation of a double membrane vesicle called a phagophore.  This double 
membrane vesicle can then engulf various cell organelles, specifically damaged 
mitochondria, peroxisomes or endoplasmic reticulum, forming the 
autophagosome (Gozuacik and Kimichi, 2004).  The autophagosome can then 
fuse with the lysosome and digest the organelles to basic amino acids and 
theoretically provide energy.  This process is controversial because the recycling 
of degraded products may be aiding in survival, or approach a critical threshold 
and result in cell death (Alva et al, 2004).  
 This autophagic response has been observed in response to a growing 
number of investigative chemotherapy agents.  (Arthur et al, 2007; Cui et al, 
2007).  The development of resistance to apoptotic machinery and specifically 
the general lack of sensitivity to chemotherapy of metastatic cancers contribute 
to the potential utility of autophagic cell death (programmed cell death II) as a 
target for novel chemotherapeutic agents.  Metastatic disease is notoriously 
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resistant to common therapies and the possibility of exploiting autophagy as a 
primary mechanism of cell killing could be beneficial.    
  After the initial disruption and cell killing, the cells may also be forced into 
a state of reproductive death where they still metabolize but are no longer 
replicating (Weaver et al, 2005; Vicencio et al., 2008).  It has also been shown 
that senescent cells release cytokines that can promote removal via the immune 
system (Bartek et al., 2008; Xue et al., 2007). In a similar fashion, autophagic 
cells may have a component to trigger activation and clearance by the innate 
immune system (Thornburn et al., 2009). 
C. Mitotic Catastrophe 
Mitotic catastrophe has long been recognized as a mode of cell death, but 
understanding the mechanisms that promote mitotic catastrophe has posed a 
long-standing challenge (Castedo et al, 2004).  The current understanding is that 
mitotic catastrophe is cell death resulting from aberrant mitosis as a 
consequence of deficient cell cycle checkpoints (Vakifahmetoglu et al., 2008). 
 The cells prematurely enter into mitosis and the attempt of the cellular 
machinery to separate aberrant chromosomes may result in the formation of 
micronuclei and nuclear fragments (Erenpreisa et al, 2001).  Cells which undergo 
mitotic catastrophe slip past cell cycle checkpoints leading to arrest in late stages 
of cell cycle (Vakifahmetoglu et al, 2008).  This study also mentions that mitotic 
catastrophe may be a pre-stage for apoptosis. The JG-03-14 compound has not 
been shown to promote the formation of micronuclei and the treated cells do not 
16 
 
 
 
 
appear to contain bifurcated nuclei (Arthur et al, 2007). This mechanism of cell 
death remains ambiguous and requires further understanding before it can be 
exploited in chemotherapeutic investigations.  
VI. Senescence 
The term replicative senescence refers to the inability of a cell to divide 
indefinitely (Campisi et al., 2007).  Most cancer cells have an enzyme called 
telomerase that creates an extension of the telomeric DNA with each division and 
allows for immortality and unlimited proliferation (Campisi, 1997). Studies have 
also shown that cancer cells will respond to chemotherapy with a similar form of 
reproductive death, termed accelerated senescence (Di et al, 2009). Accelerated 
senescence can occur in response to DNA damage induced by radiation or 
chemotherapy.  A recent commentary described how, in response to 
chemotherapeutic agents, cells can activate the ATM/ATR pathways which will 
phosphorylate chk1/chk2 (Gewirtz et al., 2008).  This phosphorylation will have 
multiple downstream effects including the phosphorylation and activation of p53. 
The phosphorylation of p53 has also been shown to activate p21, which can 
inhibit cyclin dependent kinases. Cyclin dependent kinase inhibition leads to 
activation of the Rb protein through dephosphorylation.  This dephosphorylation 
permits Rb to interact with E2F and promote this accelerated senescence (Di et 
al, 2009; Gewirtz et al, 2008). This arrest theoretically will allow time for the cell 
to repair DNA in to avoid passing the damaged DNA to daughter cells 
(DiLeonardo, 1994).   The induction of accelerated senescence and pathway 
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description is with regards to DNA damaging agents such as topoisomerase 
poisons and ionizing radiation (Di et al, 2009).   
The JG-03-14 compound has been shown to induce senescence in p53 wild-type 
MCF-7 cells but not the mutant p53 MDA-MB-231 (Arthur et al, 2007).  This 
senescent response appears to occur in the residual cells and not as the primary 
mechanism of action. The growing intimacy between autophagy and senescence 
may indicate that JG-03-14 induces autophagy and cells either die or enter into a 
state of senescence (Arthur et al., 2007; Narita et al., 2009; Vicencio et al, 2008).   
This may implicate autophagic cell death as a bridge in residual cells to undergo 
senescence possibly through the generation of reactive oxygen species (Di et al, 
2009).  Adding to the intimacy between these pathways, the inhibition of 
autophagy or sequestration of reactive oxygen species have been shown to 
attenuate senescence and in some cases increase the amount of apoptotic cell 
death (Young et al, 2010; Di et al, 2009).   
VII. The Conjugated Pyrrole, JG-03-14 
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The compound currently under investigation is a di-brominated conjugated 
pyrrole, which has shown cell-killing effects in multiple cell cancer cell lines 
(Arthur et al, 2007; Mooberry et al, 2007; Nguyen, MS Thesis).   Pyrroles are 
components of more complex macrolides that contain multiple aromatic rings 
(Juselius et al, 2000).  These pyrrole compounds and analogs such as 
imidazoles and lamellarins are widely being investigated as pre-clinical anti- 
cancer therapies (Bright et al, 2010; Iguchi et al, 2002; Baunbæk et al, 2008). 
 Early investigations have found that the JG-03-14 and its analogs bind to the 
colchicine-binding site of tubulin and have depolymerizing effects on 
microtubules (Mooberry et al, 2007).  This latter study also demonstrated that 
JG-03-14 has similar efficacy in competitive binding assays to Combretastatin A-
4 and [H-3] colchicine.  JG-03-14 has also been shown to be effective at killing 
MCF-7, MCF-7/E6, and MDA-MB-231 and 4T-1 metastatic breast tumor cells, 
HCT-116 colon carcinoma cells, and B16F10 melanoma cells through both 
autophagy and apoptosis possibly independent of p53/p21 induction (Arthur et al, 
2007; Mooberry et al, 2007; this thesis).  These cell lines include both p53 wild 
type such as MCF-7 cell lines, HCT-116 cell line and B16F10 cell line.  The 
MDA-MB231 is of the p53 mutant genotype.  
In addition to direct antitumor effects, JG-03-14 has been reported to 
prevent, as well as disrupt existing endothelial vessel formation (Daylot-Herman 
et al, 2009).  The concentrations of JG-03-14 determined to inhibit endothelial 
function were found to be sub-toxic in comparison to colchicines and nocadozole 
which required concentrations high enough to induce apoptosis of the endothelial 
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cells (Daylot-Herman et al, 2009).  Colchicine cannot be used clinically because 
it is extremely toxic to patients and is also a substrate for the p-glycoprotein 
pump (Druley et al, 2001; Mooberry et al, 2007).  Our compound of interest, JG-
03-14, is not a substrate for the multi drug resistance P-glycoprotein pump, which 
should be a decided advantage over other compounds of the same class 
(Mooberry et al, 2007).   
Considering the demonstrated need for effective therapies against 
metastatic colon cancer and the high propensity for melanoma to metastasize, 
we evaluated whether this compound would be effective against tumor cell lines 
derived from these malignancies.  Our aim with this series of studies was to 
further enhance the understanding of the JG-03-14 compound with regards to 
apoptosis, autophagy and senescence.  To prove that autophagy is acting as a 
primary mechanism of cell killing and show that apoptosis and senescence are 
intimately linked to the process. Another goal was to expand on the effects of this 
microtubule poison in a variety of cell lines and investigate the advantages of an 
anti-angiogenic conjugated pyrrole as a potential chemotherapeutic drug. 
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CHAPTER 2 Methods and Materials 
 
 
 
Cell Culture HCT116 colon carcinoma cells were obtained from ATCC and kept 
frozen in 10% DMSO (Sigma Chemical, St. Louis, MO) with Fetal Bovine Serum 
(FBS) (GIBCO Life Technologies, Gaithersburg, MD) until use.  HCT-116 cells 
are quickly thawed and cultured in a T75 flask (Cellstar) in basal RPMI 1640 
medium supplemented with 5% fetal bovine serum, 5% bovine calf serum, 2 mM 
L-glutamine, and penicillin/streptomycin 0.5 ml/100 ml medium (10,000units/ml 
penicillin and 10 mg/ml streptomycin, GIBCO Life Technologies, Gaithersburg, 
MD) at 37° C under a humidified, 5% CO2 atmosphere.  B16F10 murine 
melanoma cells were generously provided by Dr. Kimber White from ATCC and 
kept frozen and harvested the same as described for HCT-116. B16F10 cells 
were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum, 
2 mM L-glutamine, penicillin/streptomycin 0.5/100 mL (10,000 units/ml penicillin 
and 10 mg/ml streptomycin), 1M HEPES and 7.5% NaBicarbonate (GIBCO Life 
Technologies, Gaithersburg, MD and Sigma-Aldrich). H9c2 rat embryonic 
cardiomyocytes were thawed and plated as described above.  H9c2 cells were 
maintained in culture with DMEM medium supplemented with 10% fetal bovine 
serum, and streptomycin/penicillin as described above.   
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All Cells were passaged at 80% confluency by washing one time with 1X 
PBS(GIBCO) and harvested with trypsin-EDTA 0.25 %(GIBCO) then deactivated 
with RPMI medium, collected and centrifuged at 15,000 rpm for 3 minutes.  
Medium was aspirated and fresh media is added to the cell pellet; cells were 
resuspended in media and 300 µL of the cell resuspension was placed into a 
fresh T75 flask with 10mL RPMI medium.  For all culture experiments, cells were 
plated and permitted to adhere overnight before drug treatment.  Unless 
otherwise indicated, all treatment involved continuous drug exposure.     
 
 
MTT assay 5,000 cells in150µL media were plated in each well of a 96 well dish 
and allowed to adhere overnight before drug treatment.  After 48 hours, 100 µL of 
the MTT solution ( 2mg/mL PBS prepared in the dark) was added to each well 
and incubated for 3 hours at 37° C The MTT solution was removed, 100µL of 
DMSO was added to each well, and the blue dye was allowed to dissolve for 5 
minutes.  An absorbance reading was taken at 490 nm (KC Junior software, 
EL800 Universal Microplate Reader).  
   
   
Time Course of Drug Effects on Viable Cell Number and Proliferative 
Recovery Cells were plated at 1x106 cells per 96 mm Petri plate (CellStar) and 
allowed to adhere overnight.  At the various time points, the drug was aspirated 
and cells were washed once using 1X PBS.  Cells were then harvested and 
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centrifuged at 15,000 rpm for 3 minutes and media was removed.  The cell pellet 
was resuspended in fresh media and 10µL  of the cell resuspension was added 
to 90µL  of trypan blue exclusion dye (1:9; trypan blue: PBS).  10µL  of the 
mixture was placed onto a hemocytometer and viable cells (those that excluded 
the dye) were counted in 4 separate quadrants (each quadrant containing  16 
squares).   
 
DAPI Staining Hoechst dye for Apoptosis and Mitotic Catastrophe At the 
various time points, both adherent and non-adherent cells were harvested and  
centrifuged at 15,000 rpm for 3 minutes.  The media was aspirated and fresh 
media was added to resuspend the pellet.  Cell number was determined using 
trypan blue exclusion.  A dilution of 20,000 cells in 200 µL  of 1X PBS per slide 
were prepared and cells were spun at 10,000 rpm for 5 minutes (Shandon 
Cytospin 4, Thermal Electron Corp). Slides were refrigerated until ready for 
staining.  Cells were fixed with 4% formaldehyde in PBS for 10 minutes at room 
temperature, and then washed with PBS twice for 5 minutes at room 
temperature.  A 1:2 dilution of acetic acid and ethanol was used to fix the cells at 
20° C for 5 minutes.  The slides were then washed twice with PBS for 5 minutes 
at room temperature.  A 1:1000 dilution was prepared for Vectashield :Dapi and 
each slide was mounted with 10µL  of the solution.  Coverslips were sealed using 
clear nail polish and photographs were taken with a 10X objective lens using a 
Nikon fluorescence microscope and an Olympus camera.  Slides were stored at 
4°C , and three fields per condition were evaluated.  
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Both adherent cells and supernatant were collected at various time points 
and centrifuged at 1200 rpm for 5 min at 5°C.  Cells were then resuspended in 5 
mL of PBS and centrifuged again.  Supernatant from the centrifuge was 
aspirated and cells were then resuspended in 0.075 M KCl by finger tapping and 
allowed to incubate for 8 minutes at room temperature.  Cells were again 
centrifuged and supernatent was aspirated.  Cells were then fixed in the pellet 
with a 3:1 ratio of methanol and glacial acetic acid.  Samples were then 
dispersed on a slides moisturized with deionized water.  Slides were stored 
overnight to dry.  To stain the cells, Hoechst dye was diluted to 1:500 dilution of 1 
mM Hoechst 33342 in nanopure water for 10 minutes at room temperature.  The 
slides were then rinsed once and sealed similar to slides for DAPI.   
 
TUNEL staining for apoptosis 
The method of Gavrieli et al. was utilized as an independent assessment of 
apoptotic cell death in combined cytospins containing both adherent and non-
adherant cells, as reported previously (Elmore et al., 2002; DeMasters et al., 
2006). Cells were fixed and fragmented DNA in cells undergoing apoptosis were 
detected using the In Situ Cell Death Detection Kit (Roche), where strand breaks 
are end labeled with fluorescein dUTP by the enzyme terminal transferase. 
   
Flow Cytometry  Cells were plated at 3x 106 million cells per 96 mm Petri plates 
for each time point and allowed to adhere overnight.  Setup was prepared for day 
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5 and worked backward so that all treatments would complete on the same date.  
Drug treatment was initiated the following day and drug was left on the cells for 
continuous exposure.  Upon the completion of treatment, media was aspirated 
and cells were washed one time with 1X PBS.  Cells were harvested using 
trypsin and deactivated with 10ml media, then centrifuged at 15,000 rpm for 3 
minutes.  Media was aspirated and the cell pellet was resuspended in fresh 
media.  Cell numbers were determined using trypan blue exclusion dye.  At least 
1x10 6  cells per condition were used in the cell cycle analysis.  1.5 mL of 
Propidium iodide stain with RNAse was added to each aliquot of 1x10 6  cells.  
The cell suspension was filtered through a 70 micron mesh 2 times.  All samples 
were covered in aluminum foil and refrigerated until the next day.   FACs 
acquisition was performed using the EPICS 753 flow cytometer (Coulter 
Electronics, Hialeah, FL) using a 488 nm argon laser and standard optical 
emission filters.  A minimum of 13,000 events were collected per sample.  
Cellular DNA distributions were analyzed at the various stages of the cell cycle 
using Cytologic Software (Coulter Electronics).  
   
Acridine Orange and Monodansylcadaverine staining for autophagy As a 
marker for autophagy, the acridine orange staining method described by Paglin 
et al, 2001 was used.  Cells were plated at 2 x 105 per 6 well plate and allowed to 
adhere overnight.  Drug was added the following day and left on for continuous 
exposure.  At the final time point, the drug was removed and cells were washed 
one time with 1X PBS.  Cells were then stained with acridine orange (1ug/ml) for 
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15 minutes.  Monodansylcadaverine(MDC) is another marker for autophagy that 
stains the autophagic membrane (Niemann et al, 2000).   MDC(Sigma) was 
dissolved in DMSO and diluted to 0.1 mM.  At selected time points, cells were 
stained with 0.1 mM monodansylcadaverine for 10 minutes.  The stain was 
removed and cells were washed with 1X PBS four times before fresh media was 
added to the wells.  Pictures were taken with the inverted Nikon fluorescence 
microscope and an Olympus camera with 20X objective lens.    
   
Transfection with RFP-LC3 HCT-116 HCT-116 cells were prepared from frozen 
stock and passaged twice at least 2 days before nucleofection.  1x106  cells were 
centrifuged and suspended in a pellet.  100 µL of the Nucleofector V 
(Nucleofector Kit V, Amaxa) mix was added to to resuspend the cells.  The 
resuspension was added to 1 µg of the RFP-LC3 vector and the entire 
suspension was transferred to the cuvette.  The cuvette was placed in the 
Nucleofector device and program D-032 was used to transfect the cells.  500 µl 
warm medium was added to the transfected solution and the total suspension 
was transferred to a Petri plate.  These steps were repeated for the positive and 
negative controls using 2 µg of empty-GFP, and 2 µg pmax-RFP.  Stable 
transfection was maintained using Gentimycin at 1µg/125 mL.   
   
Electron Microscopy Cells were harvested from culture and 1x105 cells were 
plated per plate on Permanox Petri dishes.  Various drug treatments were 
performed until endpoint.  At each time point, cells were washed with 1X PBS 
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and then fixed with 2% paraformaldehyde/2 % glutaraldehyde in 0.1M sodium 
cacodylate buffer.  After 1 hour at room temperature, fixative was removed and 
replaced with 0.1M sodium cacodylate buffer, pH 7.4. Plates were then fixed in 
1% osmium tetroxide in 0.1M-cacodylate buffer for one hour, after which they 
were rinsed in 0.1M cacodylate buffer for 5-10 minutes.  The plates were then 
dehydrated in graded ethanol series:  50%, 70%, 80%, 95%; for 5-10 minutes 
each.  Then cell plates were dehydrated in 100% ethanol 3X, 10-15 minutes 
each.  This was followed by propylene oxide 3X, 10–15 minutes each.  Cells 
were then infiltrated with 50/50 mix of propylene oxide and PolyBed 812 resin 
mix overnight. Next, the cells were infiltrated with pure PolyBed 812 resin 
(Polysciences, Inc.)  mix hours and overnight.  The cells were placed in 
embedding containing PolyBed 812 and placed in 60˚C oven overnight to 
polymerize.  Sectioning was done using Leica EM UC6i Ultramicrotome (Leica 
Microsystems).  Semi-thin sections for light microscopy (0.5µm – 1.0µm) were 
collected on glass microscope slides and stained with 0.1% toluidine blue/0.1% 
azure II/0.1% methylene blue in 1.0% sodium borate.  For electron microscopy, 
70-90 nm thick sections were collected on copper mesh grids and stained with 
5% uranyl acetate and Reynold’s lead citrate.  Images were taken using JEOL 
JEM-1230 TEM  (JEOL USA, Inc.) with the Gatan Ultrascan 4000 digital camera 
(Gatan Inc, Pleasanton, CA). 
    
Western Blotting After the indicated times, cellular proteins were extracted from 
treated cells 1x106 using 100 to 200 µL of 1X Tris lysis buffer (1 M Tris(pH 6.8), 
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10% SDS, and dH2O) containing protease inhibitors with boiling for 5 minutes.  
Protein concentration was determined with a Lowry protein assay and 10 µg of 
total cell lysates were separated using 12% SDS-PAGE.  Proteins were 
transferred onto nitrocellulose membrane for 1 hour and blocked in TBS-Tween 
20 buffer containing 5% nonfat dry milk.  Membranes were then immunoblotted 
with the respective primary antibodies overnight in 20°C.  The following day, the 
membrane was incubated with horseradish peroxidase-conjugated secondary 
antibody for 1 hour.  Signals were detected using an enhanced 
chemilluminescence detection reagents from Pierce (Rockford, IL).   
 
Beta-galactosidase Staining for Senescence Senescence was determined 
based on β-galactosidase staining in the HCT-116 after exposure to indicated 
drug treatments. Cells were washed twice with PBS and fixed with 2% 
formaldehyde, 0.2% glutaraldehyde for 5 min. The cells were washed again with 
PBS and stained with a solution of 1 mg/mL 5-bromo-4-chloro-3-inolyl-β-
galactosidase in dimethylformamide (20 mg/mL stock), 5 mM potassium 
ferrocyanide, 5 mM potassium ferricyanide, 150 mM NaCl, 40 mM citric 
acid/sodium phosphate, pH 6.0, and 2 mM MgCl2. Following overnight incubation 
at 37 °C, the cells were washed twice with PBS and the images were capture for 
visualization. 
 
Clonogenic Survival  Clonogenicity were determined with 72 hours of drug 
treatment followed by washing of cells and replacement with fresh media.  Plates 
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were washed 1x with PBS prior to fixation with 100% methanol for 10 minutes.  
After removal of methanol, plates were stained with crystal violet dye (1%) in 
deionized water for 10 minutes.  Colonies were based on visual staining.  Vehicle 
treated, JG-03-14 10nM and 100nM all received 500 cells while JG-03-14 250nM 
and 500nM receive 2500 cells.  Treatment groups were corrected for plating 
efficiency.  
DCF Staining for Reactive Oxygen Species 
Cells were plated in 6-well plates at a density of 5x104  per well.  After treatment 
cells were incubated with 50 µM non-fluorescent DCF and intracellular reactive 
oxygen species were visualized when di-acetate group are hydrolyzed to 
fluorescent 2’, 7’dichlorofluorescein upon interaction with reactive oxygen 
species. Images were taken using the same methodology as acridine orange and 
MDC. 
Statistical Analysis 
Statistical analysis was performed using the Statview computer software. 
ANOVA testing was performed and post-hoc analysis determined significance 
base on a p-value of P<0.05. 
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CHAPTER 3 Results 
 
Part I.  Effects of JG-03-14 on HCT-116 colon carcinoma cells 
   
I. Growth inhibition of HCT-116 colon cancer cells by JG-03-14.  
 
Initial studies evaluated the sensitivity of HCT-116 colon carcinoma cells to JG-
03-14 using the MTT dye assay (Mosmann, 1983).  Cells were exposed to JG-
03-14 continuously for 48 hours prior to assessment of viable cell number.  JG-
03-14 was ineffective at a concentration of 100nM, but produced > 50% growth 
inhibition at 250nM, and > 70% inhibition at 500nM (Figure 1), findings similar to 
what were reported previously in breast tumor cells (Arthur, 2007). All 
subsequent studies were performed using JG-03-14 at a concentration of either 
250nM or 500 nM.  Sensitivity to Combretastatin A-4 was intended as a positive 
control. 
Cells were also assessed for clonogenic capacity after the initial 72 hours 
treatment. Cell number was corrected for plating efficiency and calculated as a 
percent of control.  Table 1 indicates that treatments of HCT-116 cells with JG-
03-14 at concentrations of 250 nM and 500 nM showed loss of colony forming 
capacity of 95% and 98%, respectively (Table I).  
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II. Cell death induced by JG-03-14.  
 
In order to distinguish between the effects of JG-03-14 on cell growth and on 
overall viability, we monitored cell viability by trypan blue exclusion in cells 
continuously exposed to JG-03-14 over a period of 5 days.  Figure 2 shows a 
time dependent decline in the number of viable HCT-116 cells upon continuous 
exposure to JG-03-14 at 500nM, a concentration that was previously found to be 
effective in promoting breast tumor growth arrest and cell death (Arthur, 2007). 
The figure inset clearly demonstrates that the tumor cells exposed to JG-03-14 
were dying, with approximately 95% of the HCT-116 cells lost after a period of 3 
days.   
 III. Assessment of the mode of cell death 
In previous studies, we have reported that JG-03-14 promotes primarily 
autophagy in p53 wild type MCF-7 cells and both autophagy and apoptosis in 
p53 mutant MDA-MB231 cells (Arthur, 2007). As HCT-116 cells are wild type in 
p53, it was our expectation that cell death might also occur primarily via 
autophagy. Nevertheless, we also examined the possibility of both apoptosis and 
mitotic catastrophe in response to treatment with JG-03-14. Apoptosis was 
assessed based on nuclear fragmentation by Hoechst, DAPI and TUNEL 
staining. Autophagy was evaluated based on acridine orange and 
monodansylcadaverine staining, electron microscopy as well as redistribution of 
RFP-LC3 and autophagic flux using p62. Mitotic catastrophe was based on the 
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formation of bi-nucleated cells with micronuclei (DeMasters et al, 2006).  Figure 3 
shows the untreated vehicle control with a clearly defined intact nucleus. With a 
few isolated exceptions, the nuclei of cells treated with JG-03-14 were intact 
although significantly enlarged in comparison to control cells, with little evidence 
for either apoptosis (Figure 3A) or mitotic catastrophe using a higher 
magnification with Hoechst (Figure 3B). The absence of apoptosis was also 
confirmed by absence of TUNEL positive staining (Figure 7C) and supported by 
FACS analyses performed previously by Tuyen Nguyen (MS Thesis, 2008).  In 
contrast, taxol promoted extensive nuclear fragmentation, indicative of apoptosis 
while combretastatin treatment resulted in mitotic catastrophe (Bartek & Lukas, 
2001). 
Previous work by Ms. Nguyen also indicates that JG-03-14 transiently 
arrested 66.4% of the HCT-116 p53 wild type tumor cells in the G2/M cell phase 
after the first day of treatment. This G2/M block persisted for at least 72 hours.  
After 72 hours, the cell cycle distribution shifted, with 63% of the cells in G2/M 
and 4.5% in G1, with a very small sub G1 population. Of particular interest was 
the observation that these p53 wild type cells appear to continue to replicate their 
DNA following the G2/M arrest, resulting in a hyper diploid population.  This 
effect was observed after the first day of treatment and the hyper diploid cell 
population had more than doubled after 72 hours.  In contrast, Taxol arrested 
41.72% of cells in the G1/G0 phase after just 24 hours, and this cell cycle 
distribution grew to 59.76% after 72 hours. 
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In summary, only a small fraction of the cell population could be detected 
in the sub G1 phase both at 24 and 72 hours following the initiation of treatment 
with 500 nM JG-03-14, confirming that apoptosis likely plays only a minor role in 
cell death induced by JG-03-14 in the HCT-116 cells.  
In contrast to the relative lack of apoptosis, there was extensive evidence 
of autophagy after treatment with JG-03-14 in the HCT-116 cells.   Figure 4A 
shows that control HCT-116 controls stained with acridine orange had a single 
large vesicle that was situated near the nucleus; in contrast, extensive punctuate 
distribution of small acidic vesicles within the cytoplasm, indicative of autophagy, 
was observed in cells treated with JG-03-14. The cells treated with JG-03-14 
were also quite enlarged, nearly double the size of the untreated cells.   
Utilizing monodansylcadaverine, a stain that binds to the lipid membrane 
of the autophagosomes, results in similar patterns to what was observed with the 
acridine orange staining. Specifically, as shown in figure 4B, the controls show a 
single vacuole closely associated with the cell nucleus while the cells treated with 
JG-03-14 show a highly distributed punctuate pattern throughout the cytoplasm.  
 
LC3-II is a cleaved product of LC3-I and is involved in the formation of 
autophagosomes (Kabeya et al, 2000).  We further monitored the distribution 
of LC-3 II in the treated cells.  HCT-116 colon tumor cells were transfected with 
an RFP-LC3 vector via nucleofection and the cells were observed under 
fluorescence after 72 hours of exposure to 500 nM JG-03-14.  After 72 hours of 
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drug treatment, the transfected cells showed a punctuate distribution of LC-3 II 
proteins in the cytoplasm, again consistent with the promotion of autophagy 
(Figure 5A).   
In order to further confirm autophagic flux, we monitored p62 protein 
expression.  This is a scaffold protein associated with autophagic membrane 
formation.  The flux and degradation of p62 indicates that the autophagic 
machinery is in effect degrading the membrane to completion (Bjørkøy et al, 
2009).   In HCT-116 cells treated with 500 nM JG-03-14 for 48 hours, we 
observed a clear reduction in p62 protein expression.  This reduction was also 
inhibited with a late stage autophagic inhibitor, Chloroquine (Figure 5C).  
Starvation was included as a positive control for degradation of p62. 
Another method to visualize autophagic vesicle formation is the use of 
electron microscopy imaging (Ylä-Anttila, et al., 2009).  This is a gold standard 
for vesicle formation. The image in figure 5B clearly shows the induction of 
autophagic vesicles after 72 hours of treatment with 500 nM JG-03-14. 
 
 IV.  Effect of autophagic inhibition on JG-03-14 induced cyto toxicity  
The role of autophagy is still undefined and appears to have a role in both 
cell protection and cell killing.  In efforts to confirm that JG-03-14 is killing the 
HCT-116 cells through autophagic processes, studies assessed the impact of 
inhibition of autophagy on tumor cell sensitivity to JG-03-14.   As shown in figure 
6A, the concurrent treatment of cells with JG-03-14 and chloroquine was only 
slightly protective.  Chloroquine is a lysomotropic inhibitor, which merely 
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maintains pH and prevents acidification of autophagic vesicles, only preventing 
the last step of autophagy (Shintani et al., 2001).  In figure 6B, it is clear that 
chloroquine produces a blockade to autophagy, as shown by condensed 
fluorescent staining.   More quantitative evidence that chloroquine blocks 
autophagic flux is provided by figure 5B, which shows that concurrent treatment 
with JG-03-14 and chloroquine protected p62 from degradation. 
The fact that inhibition of autophagy did not provide complete protection to 
the cells suggested that a blockade to autophagy was likely to be leading to an 
alternative mode of cell death, specifically apoptosis.  Figure 6C clearly shows a 
large increase in TUNEL positive staining for concurrent treatment with JG-03-14 
and chloroquine.  Combretastatin A-4 is utilized as a positive control for induction 
of apoptosis. 
V. Promotion of senescence and lack of proliferative recovery in residual 
surviving cells    
In previous studies, we have reported that residual cells that appear to have 
survived the drug treatment were in a state of senescence arrest (Arthur, 2007); 
in some reports, senescence has been succeeded by proliferative recovery 
(Sliwinska, 2009; Elmore et al., 2005). In the current studies, we observed that 
the residual cell population that survives the initial cytotoxic effects of JG-03-14 is 
arrested in state of senescence, based on beta-galactosidase staining as well as 
cell enlargement and spreading (Figure 7A).  Three days post treatment, nearly 
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100% of the residual surviving population stained positively for beta 
galactosidase (Figure 7B).  
Although senescence is generally thought to be irreversible, we have observed 
recovery of proliferative capacity in breast tumor cells subsequent to treatment 
with either doxorubicin or radiation (Sliwinska, 2009; DeMasters, 2004; Jones et 
al., 2005). In order to determine whether the cells exposed to JG-03-14 had lost 
self-renewal capacity, drug was removed after 3 days, and cell number was 
followed for an additional 17 days. However, we failed to detect any evidence of 
re-growth, indicating that the cells had apparently lost all reproductive capacity 
(Figure 7C). 
 
VI. Reactive Oxygen Generation as Possible Role in Toxicity 
 
The studies in Figure 8 compared reactive oxygen generation by JG-03-
14, taxol, and combretastatin by DCF staining generated significantly less 
reactive oxygen after 72 hours than the other compounds (Figure 8).  This 
reactive oxygen generation likely contributes to the toxicity generated by these 
clinical therapeutic agents, specifically cardiotoxicity and peripheral neuropathy 
(Kim et al, 2004). 
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Table 1 – Clonogenic Survival following exposure with JG-03-14 (% control) 
250 nM 500 nM 
4.65 ± 0.07* 1.65 ± 0.25* 
Values represent average colonies formed 2 weeks post 72 hours treatment with 
JG-03-14 
* P= <0.0001 compared to Control group 
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Figure 1. Sensitivity to JG-03-14 in HCT-116 cells. Cells were exposed to JG-
03-14 at the indicated concentrations for 48 hours and cell number was evaluated 
using the MTT dye assay. Values shown are from a representative experiment 
with quadruplicate samples for each condition. Studies were reproduced in 3 
additional replicate experiments. Error bars reflect standard deviations and 
significant differences from DMSO treatment are indicated by *  (P<0.05), which 
were assessed by the ANOVA and Tukey/Kramer post-hoc analysis. 
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Figure 2. Time dependent loss in cell viability by exposure to JG-03-14. HCT-116 
cells were either continuously exposed to DMSO or 500nM JG-03-14 and viable cell 
number was monitored by trypan blue exclusion over a period of 5 days. Values shown 
are from a representative experiment with triplicate samples for each condition. Studies 
were reproduced in 3 additional replicate experiments. The inset shows the decline in 
viable cell number using an expanded Y-axis. Significance differences from DMSO 
treatment are indicated by *  ( P<0.05) and were assessed by ANOVA and Fisher’s PLSD 
post-hoc analysis.  
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Figure 3. Images of HCT-116 cells exposed to JG-03-14. HCT-116 cells were 
treated with 500nM JG-03-14 for 72 hours. Apoptosis (nuclear fragmentation) and 
mitotic catastrophe (bi-nucleated cells with micronuclei) were evaluated based on 
morphology by DAPI (A) and Hoechst dye (B) staining, respectively.  Magnifications 
shown are 200X and 400X, respectively. 
 
 
 
 
 
 
 
 
40 
 
 
 
 
 
 
 
A. 
 
 Day 2 Day 3 
DMSO 
  
JG-03-
14 
(250 
nM) 
  
 
 
B. 
 
MDC  DMSO JG-03-14 (250 
nM) 
JG-03-14 (500 
nM) 
Day 3 
 
 
Figure 4. Staining for autophagy in HCT-116 cells exposed to JG-03-14. HCT-116 
cells were treated with 500nM JG-03-14 continuously and autophagy was assessed 
based on acridine orange staining ( A) and monodansylcadaverine staining (B) at 48 
and 72 hr. Magnifications shown are 200X. 
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Figure 5. Confirmation of autophagy by JG-03-14 in HCT-116 cells. HCT-116 
cells were treated with 500nM JG-03-14 continuously and autophagy was 
assessed based on redistribution of RFP-LC3 (A) and electron microscopy (B) at 
48 and 72 hr. Magnifications shown as 200X for RFP, and a representative scale-
bar for EM.  Autophagic flux (C) was assessed based on the degradation of p62 
and all treatments were performed for 48 hours. Chloroquine was used either 
independently or concurrently at 10 µM. 
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Figure 6. Influence of chloroquine on sensitivity to JG-03-14.  HCT-116 cells 
were continuously exposed to 500 nM JG-03-14, 10 µM Chloroquine, or the 
combination treatment for the indicated times. Trypan blue was utilized for measure 
of cell viability (A), autophagy was visualized by MDC (B), and both adherent and 
non-adherent cells were collected for the TUNEL assay to measure apoptosis (C).  
Values shown are from a representative experiment with triplicate samples for each 
condition. Studies were reproduced in two additional replicate experiments. 
Significance differences from DMSO treatment are indicated by * (P<0.05) and were 
assessed by the two-way ANOVA and Fisher’s PLSD post-hoc. 
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Figure 7. Induction of senescence and lack of proliferative recovery in HCT-
116 cells treated with JG-03-14. HCT-116 cells were treated with 500nM JG-03-
14 for 72 hours, drug was  removed and replaced with drug free medium.  
Medium was replaced every 3 days.  A. Senescence in residual surviving cells by 
beta-galactosidase staining. B. Three representative fields were quantified and 
counted as postive or negative for beta-galactosidase staining. C. Viable cell 
number. Significance differences from DMSO treatment day 3 are indicated by * 
(P<0.05) and were assessed by the two-way ANOVA and Fisher’s PLSD post-
hoc. 
 
 
 
47 
 
 
 
 
 
 
 
 
 
B. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
 
 
 
 
 
 
 
 
C. 
0
200000
400000
600000
800000
1000000
1200000
1400000
1600000
Day 0 Day 3 Day 5 Day 7 Day 10 Day 13 Day 16 Day 20
Vi
ab
le
 C
el
l N
um
be
r
  
* * * *
 
 
 
 
 
 
 
 
 
 
 
 
49 
 
 
 
 
ROS DMSO JG 500 nM Taxol 100 
nM 
Combretastat
in A-4 100 
nM 
Natural 
Light 
  
Stained 
  
 
 
 
 
 
 
 
 
 
Figure 8.  DCF stain Assessment of Induction of Reactive Oxygen Species.  
HCT-116 cells were continuously exposed to 500 nM JG-03-14, 100 nM taxol 
and 100 nM combretastatin A-4.  Residual cells were stained using DCF 
fluorescent stain and images were taken at 400x magnification. 
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Results B. Effects of JG-03-14 in B16F10 melanoma cells 
 
 
I. Effects of JG-03-14 on viability of B16F10 murine melanoma cells.  
 
In an effort to extend the utility of the JG-03-14 compound to additional 
tumor models; studies of drug action were performed in B16F10 murine 
melanoma cells.  Figure 9 indicates that JG-03-14 produced a concentration-
dependent reduction in clonogenic survival, with substantial effects evident at 
concentrations of 250 and 500nM, similar to what was reported previously in 
breast tumor cells (Arthur, 2007).  
Table II indicates that there was a reduction of 96% and 97% when 
B16F10 cells were exposed for 72 hours to 250 nM and 500 nM JG-03-14, 
respectively.  All subsequent studies were performed using JG-03-14 at 
concentrations of either 250 nM or 500 nM (Table II).   
  
II. Cell death induced by JG-03-14.  
 
The previous clonogenic survival assay indicates a single cells ability to 
form a colony with exposure to JG-03-14.  Therefore, we also monitored the 
effects of JG-03-14 on cell viability over a period of 5 days by simple trypan blue 
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exclusion.  Figure 10 shows a time dependent decline in viable cell number when 
B16F10 cells were treated by continuous exposure to JG-03-14 at 500nM,  a 
concentration that was previously found to be effective in promoting growth arrest 
and cell death in breast tumor cells (Arthur, 2007). The figure inset clearly 
demonstrate that the tumor cells exposed to JG-03-14 were dying as early as 
day 3, and that approximately 55% of the melanoma cells were lost after a period 
of 3 days.  
 III. Assessment of apoptosis  
In previous studies, we have reported that JG-03-14 promotes primarily 
autophagy in p53 wild type MCF-7 cells and both autophagy and apoptosis in 
p53 mutant MDA-MB231 cells. As B16F10 melanoma cells are wild type in p53, it 
was our expectation that autophagic cell death would also be the primary mode 
of cell death. However, in order to examine the possibility that the cell death 
observed in B16F10 melanoma cells might be due to apoptosis, nuclear 
morphology was evaluated by DAPI staining.  Figure 11A shows the untreated 
vehicle control with a clearly defined intact nucleus. With a few isolated 
exceptions, the nuclei of cells treated with JG-03-14 were intact although 
significantly enlarged in comparison to control cells. These cells also did not 
present evidence of mitotic catastrophe, where bifurcated cells have micronuclei 
resulting from aberrant mitosis (Figure 11B). 
We also assessed the effects of other microtubule poisons (taxol, and 
combretastatin A-4, both at 100 nM) based on other publications and utilized 
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these poisons as positive controls for apoptosis.  DAPI staining showed that the 
majority of nuclei were fragmented by taxol treatment after three days (Figure 
11A).  Combretastatin treatment appeared to promote mitotic catastrophe (Figure 
11B). Consequently, the actions of JG-03-14 in terms of promoting cell death 
appear to differ markedly from that of these other microtubule poisons.  Although 
some apoptotic bodies were detected in response to JG-03-14, the percentage 
was minimal and in no way could account for the amount of cell death seen 
following treatment.   
In order to further understand the effects of JG-03-14 on B16F10, we used 
propidium iodide staining and single cell flow cytometry to quantify the cell cycle 
alterations induced by this novel microtubule poison. 
IV. Cell cycle effects of JG-03-14  
 
The next series of experiments was designed to verify the absence of 
apoptosis based on the detection of a cell population with DNA content lower 
than 2N, indicative of the DNA fragmentation that is a hallmark of apoptosis.  
FACS analysis confirmed that only a small fraction of the cell population could be 
detected in the sub G1 phase both at 24 and 72 hours following the initiation of 
treatment with 500 nM JG-03-14 (Figure 12). Again, using treatment with taxol 
and combretastatin as positive controls, we detected substantial populations of 
sub G1 cells after treatment with these microtubule poisons. These studies  
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confirm that  apoptosis likely played only a minor role in cell death induced by 
JG-03-14 in the B16F10 melanoma cell line.  
Figure 4 also presents an analysis of cell cycle distribution of B16F10 cells 
treated with JG-03-14.  JG-03-14 transiently arrested the p53 wild type tumor 
cells in the G2/M cell phase after the first day of treatment, and this G2/M block 
persisted for at least 72 hours.  After 72 hours, the cell cycle distribution shifted, 
with 38.9% of the cells in G2/M and 14.7% in G1/S. Of particular interest was the 
observation that these p53 wild type cells appear to continue to replicate their 
DNA following the G2/M arrest, resulting in a hyperdiploid population.  This effect 
was observed after the first day of treatment and the hyper diploid cell population 
had more than doubled after 72 hours, where 29.7% of the B16F10 cells were 
polyploid.   
As indicated above, FACS analysis determined that after 24 hours a very 
large population is in G2/M arrest.  However, after 72 hours there is a small 
population of cells that are sub-G1.  This percent population does not correlate 
with the extent of cell death observed.  This apparent apoptosis independent cell 
death indicated that it was important to assess alternative pathways for cell killing 
such as mitotic catastrophe and autophagy.    
 
V. Assessment of mitotic catastrophe in B16F10 melanoma cells after JG-
03-14 treatment  
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Since apoptosis could only account for a small fraction of the cell death 
observed in the B16F10 melanoma cells upon treatment with JG-03-14, it 
appeared likely that other modes of cell death such as mitotic catastrophe or 
autophagy might be responsible for the time dependent decline in cell number 
observed in the studies presented in Figure 10.  Due to the presence of enlarged 
cells and a hyper-diploid cell population we considered the possibility of mitotic 
catastrophe being the mode of cell death in B16F10 cells.  However as shown in 
figure 11B, analysis using Hoechst stained cells failed to detect evidence of bi-
nucleated cells and micronuclei that are characteristics of mitotic death 
(DeMasters et al, 2006) 
 
  VI. Induction of autophagy by JG-03-14.  
 
In our previous work, the p53 wild type MCF-7 and p53 mutant MDA-MB-
231 breast tumor cells demonstrated essentially similar sensitivity to JG-03-14; 
however, their response was different with regard to the modes of cell death. As 
in the current studies, MCF-7 cells were not dying through apoptosis based on 
FACS analysis and the TUNEL assay, but rather through autophagy while the 
p53 mutant MDA-MB231 cells demonstrated both apoptosis and autophagy.  
Consequently, we assessed the promotion of autophagy by JG-03-14 using a 
number of assays including acridine orange and monodansylcadaverine staining, 
and electron microscopy.   
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Figure 13A shows a quite extensive level of basal autophagy in the 
B16F10 melanoma cells based on the mosaic distribution in control cells, which 
is consistent with a recent time-lapse GFP-LC3 by Tormo et al., (2009). 
However, treatment with JG-03-14 resulted in an increase in puncta formation 
throughout the cell, consistent with the formation of acidic vesicles. 
To confirm the promotion of autophagy, we used an additional approach, 
staining of autophagic vesicles with monodansylcadaverine, a stain that binds to 
the lipid membrane of the autophagosomes (Niemann et al., 2001). Figure 13B 
shows a similar pattern to what was observed with the acridine orange staining. 
Specifically, the controls show a more condensed pattern of vacuoles while the 
cells treated with JG-03-14 show a highly distributed punctuate pattern 
throughout the cytoplasm. The cells treated with other microtubule poisons did 
not show enhanced formation of autophagic vesicles (Figure 13A and 13B).        
   
Another mechanism for detection of autophagic vesicles is the use of 
electron microscopy (Figure 14).  Here we show that the control cells there are 
clearly intact mitochondria and a healthy nucleus.  The B16F10 cells that have 
been treated with JG-03-14 (500 nM) show clear nuclear and cell enlargement as 
well as induction of autophagic vesicles that commence degradation of damaged 
cellular constituents.  
 
VIII. Effects of autophagic inhibitors on the response to JG-03-14 treatment 
in B16F10 cells 
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There is continuing controversy in the literature as to whether autophagy 
is a cytoprotective mechanism or an actual mode of cell death (Mori et al, 2007; 
Boya et al, 2005).  In a further attempt to confirm the mode of cell death caused 
by JG-03-14 and to elucidate the ambiguous role of autophagy, we sought to 
block autophagy.  In efforts to address this question, cells were pre-treated or 
concurrently treated with 3-methyladenine (3-MA), Wortmannin, LY-249004, 
Bafilomycin A-1 and Chloroquine, all of which have been shown to inhibit 
autophagy in a variety of experimental systems (Meschini et al, 2008; Seglen and 
Gordon, 1982; Shacka et al., 2006). However, many of these agents had intrinsic 
toxicities making it difficult if not impossible to study the effects of autophagic 
inhibition (data not shown).  The late inhibition of H-ATPase pump with 
Bafilomycin did seem to partially prevent the acidification of autophagic vesicles 
in concurrent treatment with JG-03-14 (Figure 15A).  Consequently, studies were 
conducted using Bafilomycin A-1 at 10 nM.  Figure 15B shows that Bafilomycin 
produced a modest protection against the cytotoxic effects of JG-03-14 in both 
the MTT absorbance assay as well as the Trypan Blue assay for cell viability. 
The fact that protection was relatively modest can be explained by the observed 
increase in the amount of apoptotic cells by DAPI staining (Figure 15C).    
  
VIII. Promotion of senescence and lack of proliferative recovery in residual 
cells  
   
57 
 
 
 
 
In previous studies, we have reported that residual cells that appear to 
have survived the drug treatment were in a state of senescence arrest (Arthur et 
al. 2007); in some studies, senescence has been succeeded by proliferative 
recovery (Elmore et al. 2005). In the current studies, we observe that 95% of the 
residual cell populations following treatment with 500 nM JG-03-14 are arrested 
in senescence, based on beta-galactosidase staining as well as cell enlargement 
and spreading (Figure 16A). Similarly, 91% of the cells treated with 250 nM JG-
03-14 appeared to be senescent.  The induction of senescence could be 
observed as early as day 2. Adriamycin was used as a positive control for 
senescence.  
In order to determine whether the cells had lost self-renewal capacity, drug was 
removed after 72 hours and cell number was followed for an additional 17 days. 
We failed to detect any evidence of cell re-growth for periods as long as the 
study, 20 days total, indicating that the cells had lost all reproductive capacity 
(figure 16B).  
 
IX. Relationship between Autophagy and Senescence 
A recent review by Young et al. gave insight into the relationship between 
autophagy and senescence.  Therefore we wanted to investigate whether or not 
the inhibition of autophagy in this model would have an effect on senescent cells. 
Our studies also revealed that through the inhibition of autophagy, we were able 
to attenuate senescence based on beta-galactosidase staining (Figure 15D).  
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Analysis of the images showed a 60% reduction in positive staining cells (Figure 
15E).  Interestingly, this attenuation of senescence did not appear to protect cells 
from loss of proliferative capacity (Figure 16B), but does shine light on the 
possibility of shared pathways between autophagy and senescence.  This 
population of senescent cells was quantified and presented reduction of 95% to 
38.7% and 91% to 27% for combination JG-03-14 at 500 nM and 250 nM with 
Bafilomycin, respectively (Figure 15E).  This indicates that the combination 
treatment is also promoting an alternative mode of cell death, that of apoptosis. 
    
X. Evaluation of JG-03-14 effect on cardiac cell viability 
   
To assess the potential toxicity accompanying the cancer cell killing 
effects of JG-03-14, we employed an immortalized in vitro cardiac model, H9c2 
cardiomyocytes (Zordoki & El-Kadi, 2007). Combretastatin is a microtubule 
poison currently under clinical investigation and has been shown to promote 
extensive cardiotoxiticy (Stevenson et al., 2003). Therefore, we wanted to 
determine if our compound would have an advantage over the pronounced 
toxicities of combretastatin to the heart.  Using the MTT dye assay, we found JG-
03-14 is consistently less toxic than the other microtubule poisons investigated, 
combretastatin A-4 and taxol (Figure 17).  
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Table 2. 
 
Table 1 – Clonogenic Survival assay following 72h JG-03-14 exposure (% control) 
 JG-03-14 (250nM) JG-03-14 (500 nM) 
B16F10 4.31 +/- 1.1* 2.7 +/- 0.65* 
Values represent average colonies formed 2 weeks post 72 hours treatment JG-03-14 
* P= >0.0001 compared to Control group 
* 
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Figure 9. Dose-dependent Effects of JG-03-14 on B16F10 Clonogenic Capacity 
B16F10 cells were plated based on previous dose responses. 100 cells for DMSO, JG 10 
nM and 500 cells for JG 250 nM and JG 500 nM.  Colonies were considered as greater 
than 10 cells and lacking the hallmarks of senescence.  Assay shown is a representative 
experiment done in triplicate and was corrected for plating efficiency.  Two identical 
replicate experiments were performed for confirmation. Error bars reflect standard 
deviations and significant differences from DMSO treatment are indicated by *  (P<0.05), 
which were assessed by the ANOVA and Tukey/Kramer post-hoc analysis. 
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Figure 10: Time dependent loss in cell viability by exposure to JG-03-14. B16F10 
cells were continuously exposed to 500nM JG-03-14 and viable cell number was 
monitored by trypan blue exclusion over a period of 120 hours. Values shown are from a 
representative experiment with triplicate samples for each condition. Studies were 
reproduced in two additional replicate experiments. The inset shows the decline in viable 
cell number using an expanded Y-axis. Significance differences from DMSO treatment 
are indicated by *  ( P<0.05) and were assessed by the Student t-test. 
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Figure11: Images of B16F10 nuclear integrity of cells exposed to JG-03-14. B16F10 
cells were treated with 500nM JG-03-14 for 72 hours. Apoptosis and mitotic catastrophe 
were evaluated based on morphology by DAPI staining (A) and Hoechst (B) (nuclear 
fragmentation and bi-nucleated cells with micronuclei, respectively). 
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Figure 12: Cell Cycle Distribution of B16F10 cells exposed to JG-03-14.  B16F10 cells 
were treated continuously with various microtubule poisons.  Both supernantant and 
adherant cells were collected and analyzed using propidium iodide single cell analysis 
after both 24 hours and 72 hours. 
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Figure 13. Assessment of autophagy in B16F10 cells exposed to JG-03-14 B16F10 
cells were treated with Vehicle, 500nM JG-03-14, and 100 nM Combretastatin A-4 
continuously and autophagy was assessed based on acridine orange staining 400X ( A) 
and monodansylcadaverine 200X (B) staining at 72 hours. 
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Figure 14: Confirmation of autophagy in B16F10 cells exposed to JG-03-14 
Autophagy was confirmed using electron microscopy visualization.  B16F10 cells were 
treated for 72 hours continuously prior to fixation and staining.  Scale-bars indicate 
magnification comparisons for cell enlargement. 
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Figure 15. The effect of Bafilomycin on B16F10 response to JG-03-14 The B16F10 
cells were exposed to either JG-03-14 250 nM or 500 nM and Bafilomycin 10 nM or in 
combination.  Adriamycin and Taxol used as positive controls.  Acridine orange staining 
was used as a measure of autophagy (200X) (A), as well as its protective effects on cell 
viability using trypan blue and MTT absorbance assays (B).  Also shown is the effect the 
combination had on nuclear integrity as seen by DAPI (400X) (C), attenuating effects on 
senescence (200X) (D) and quantified blue positive staining (E).  Viability assays are two 
replicate experiments combined each done in triplicate.  
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Figure 16: Senescence and destruction of proliferative recovery for B16F10 cells 
exposed to JG-03-14 B16F10 cells were treated with 500nM JG-03-14 for 72 hours, 
drug was  removed and replaced with drug free medium.  Medium was replaced every 3 
days.  Beta-galactosidase staining (A) and lack of proliferative recovery (B) is displayed 
as assessed using trypan blue trypan blue. Blue Diamonds (JG-03-14 500 nM), Maroon 
Triangles (JG + Bafilomycin 10 nM). Significant differences from DMSO treatment day 
3 for both JG alone and Combination are indicated by * (P<0.05) and were assessed by 
the two-way ANOVA and Fisher’s PLSD post-hoc. 
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Figure 17:  Effects of microtubule poisons Taxol, Combretastatin A-4 and JG-03-14 on 
H9c2 rat embryonic cardiomyocytes. H9c2 cells were treated dose dependently with nano 
molar concentrations of JG-03-14, Taxol and Combretastatin A-4.  MTT absorbance assay shows 
a concentration dependent decline in viable cell number.  Shown is a representative experiment 
performed with samples in triplicate. An identical replicate experiment was performed to 
confirm results. Significant differences from DMSO treatment day 3 for both JG alone and 
Combination are indicated by * (P<0.05) and were assessed by the one-way ANOVA and 
Fisher’s PLSD post-hoc. 
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CHAPTER 4 Discussions 
   
 The American Cancer Society estimates that in 2010 there will be over 1 million 
new cancer patients (American Cancer Society, 2010).  These astronomical 
numbers also contribute to 1 in every 4 deaths, which equal about 1500 lives per 
day. Of those, colon cancer, breast cancer and melanoma are some of the most 
deadly malignancies when not detected early.  The current microtubule targeting 
agents for metastatic disease are not very effective (Fojo et al., 2007; Sampath el 
al., 2006; Delaunoit et al., 2005).  Even when the drugs are effective, they also 
have numerous debilitating toxicities.  Cardiotoxicity, peripheral neuropathy and 
the development of drug resistance are a few of the major drawbacks associated 
with current cancer chemotherapy (American Cancer Society, 2009).  Previous 
studies from our lab have shown the effects of JG-03-14 on MDA-MB-231, MCF-
7 and MCF-7/E6 breast tumor cells, of which all appear to be sensitive to JG-03-
14 through either apoptosis or autophagy (Arthur et al., 2007).   
The primary findings of our studies are that both HCT-116 colon 
carcinoma cells and a B16F10 melanoma cell line are sensitive to the novel 
microtubule poison, JG-03-14. The initial response to treatment is cell death, 
primarily through autophagy. A residual surviving cell population is in a state of 
senescence, which appears to be irreversible, even when drug is removed as 
shown by the lack of proliferative recovery. Clonogenic survival studies indicate 
that at a concentration of 500 nM there is an approximate 98.5% reduction in 
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survival of HCT-116 cells and a 97.3% reduction in survival of the melanoma 
cells. The effects on clonogenic survival are markedly similar while the time 
course studies of cell killing demonstrate dramatic differences between the two 
cell lines.  One hypothesis for the overall decreased sensitivity of the B16F10 
cells is the high amount of what appears to be a basal autophagy, which has 
been mentioned by other groups (Tormo et al, 2009).  This basal level of 
autophagy may stage the cells to enter into senescence at a more accelerated 
rate as opposed to entering autophagic cell death, similar to what has been 
reported in response to high concentrations of adriamycin (Vicencio et al., 2008; 
Di et al, 2006, 2009).  
 
Cell Death by Autophagy 
Autophagy is a process that involves the formation of double membrane acidic 
vesicles around cellular organelles such as mitochondrial or endoplasmic 
reticulum; the autophagosomes then fuse with lysosomes that provide the 
enzymes for degradation of the autophagolysosomal content (Dunn, 1994).  In 
control acridine orange-stained cells, the cytoplasm and nucleus fluoresce bright 
green and dim red respectfully, whereas in cells undergoing autophagy, the 
acidic compartments fluoresce bright orange (Paglin et al., 2001).  Our 
observations of autophagic vacuoles in JG-03-14 treated cells stained with 
acridine orange indicate the presence of autophagolysosomes.  The untreated 
controls in both HCT and B16 cells generally show a single condensed large 
vacuole situated near the nucleus.  The literature does indicate that in some 
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cases autophagy is an alternative mode of cell death when apoptosis is defective 
due to p53 mutations or its inhibition (Kim et al., 2006; Yu et al., 2006).  However, 
since our cells are not p53 deficient, this explanation would not apply.  Other 
work has shown that autophagy may contribute to the tumor suppressive function 
of p53, (Jin 2005; Zeng et al., 2007) and that p53 may be involved in the 
induction of autophagy (Tasdemir et al., 2008; Levine et al., 2008).  
   
Autophagy was also confirmed using monodansylcadaverine staining in the both 
cell lines in response to JG-03-14. MDC is sometimes considered to be a more 
reliable indicator of autophagic vacuole formation because of its interaction with 
the autophagic membrane and not just the acidic compartment of the 
autophagosome (Biederbick et al., 1995).  Transmission electron microscopy 
further substantiated the autophagic vesicle engulfing organelles and the 
autophagic machinery being executed in both the colon and melanoma cell lines.  
 
A protein associated with autophagy is microtubule associated protein light chain 
3. LC3-II is a proteolytic product of LC3-I that is required for the formation of 
autophagosomes and is a known marker of autophagy (Asanuma et al., 2003).  
Prior to the induction of autophagy, RFP-LC3 shows a diffuse localization of red 
within the cytoplasm, whereas once autophagy is induced, the cleaved protein 
will associate with the membrane of the autophagic vesicle.  This punctuate 
pattern is indicative of the autophagic process (Zeng et al., 2007).  Our RFP-
LC3-II punctuate pattern within the cytoplasm further supports the conclusion of 
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autophagic activity after incubation with JG-03-14 in the HCT-116 cells (Niemann 
et al., 2000). We also attempted to transfect the B16F10 cells.  The RFP-LC3 
was successfully transferred and visualized, but we were not able to maintain the 
stability of the fluorescent protein. Consequently, we were unable to evaluate the 
stable expression model of the fluorescent protein in this cell line.  
 
Autophagic Flux 
 
Another protein that has provided experimental evidence for autophagy is 
p62/SQSTM1 (Moscat et al., 2009). P62 is a ubiquitous scaffold protein that is 
associated with membrane formation for autophagosomes.  During autophagic 
flux, the double membrane vesicles will fuse with the lysosome and p62 will be 
degraded (Bjørkøy et al, 2009).  Our studies demonstrate autophagic flux in the 
HCT-116 cells when treated with JG-03-14. Here again, the B16F10 cells did not 
show evidence of p62 protein expression across all treatments or controls, 
possibly due to the basal level of autophagy resulting in undetectable levels in 
our assays. We hope to use an odyssey bioluminescence assay in the future to 
amplify the protein expression and confirm if our prediction of autophagic flux is 
correct.  In HCT-116 cells, we do show a decline in p62 levels after 48 hours of 
incubation with JG-03-14 as well as partial restoration when cells are treated 
concurrently with the lysomotropic inhibitor chloroquine.    
 
Inhibition of Autophagy to validate a mode of cell death 
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In order to further confirm our findings that the primary mechanism of cell killing 
induced by JG-03-14 is autophagy; we utilized pharmacological agents to inhibit 
the autophagic process.  Chloroquine and Bafilomycin A-1 are lysomotropic and 
H+-ATPase inhibitors, respectively (Shintani et al., 2004; Yamamoto et al., 1998).  
These compounds have been shown to inhibit the fusion of the autophagosome 
and the lysosome, which in turn inhibits the last step of the autophagic process 
(Shintani et al., 2004).  In our studies, we found that the inhibitors generated 
somewhat ambiguous outcomes.  The combination of autophagic inhibitors with 
JG-03-14 seemed to have a partially protective response against cell killing. As 
the autophagic process was being inhibited, the final mechanism of cell death 
appeared to be converted to the apoptotic machinery. This blockade of 
autophagy could be visualized using MDC, acridine orange staining while 
apoptosis was detected by DAPI staining, and the TUNEL assay.  The blockade 
to autophagy in HCT-116 cells was confirmed by restoration of p62 levels while 
apoptosis was confirmed by FACS analysis.  These effects observed with JG-03-
14 and the use of concurrent autophagic inhibitors redirecting the cell to 
apoptosis is similar to what others have reported with tamoxifen (Amaravardi et 
al., 2007).   
 
Absence of apoptosis as the primary response to JG-03-14. 
It was of particular interest that JG-03-14 failed to promote extensive 
apoptosis in either the HCT-116 cells or the B16F10 melanoma cells. This may 
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be related to the fact that both cell lines are wild type in p53 and previous work in 
MCF-7 cells demonstrated primarily autophagy induced by JG-03-14 in this p53 
wild type cell line (Arthur et al., 2007). There appears to be an ambiguous role of 
p53 with regards to autophagy.  A recent paper described how both the over 
expression and silencing of p53 can induce autophagy (Tasdemir et al., 2008).  
This may correlate to the dual role of autophagy being cytotoxic and 
cytoprotective (Baehrecke, 2005).  The induction of p53 may also be cell 
protective if a DNA damaging agent activates the cell’s DNA damage response to 
arrest the cells with intentions of DNA repair and proliferation (Tasdemir et al., 
2008).  p53 induction could also be a mechanism whereby the cell has endured 
DNA damage and is poised to undergo intrinsic apoptosis as a means of cellular 
suicide (Prabhudesai et al., 2007).  With JG-03-14 treatments, we did not detect 
induction of p53.  DAPI staining studies and cell cycle analyses indicated that 
both taxol and combretastatin A-4 are killing cells through a different mechanism.  
Taxol has been shown to induce G1 arrest and apoptosis whereas 
combretastatin A-4 may drive cells into the apoptotic pathway after being pre-
staged by mitotic catastrophe (Wagenknecht et al., 1998; Blajeski et al., 2001; 
Vakifahmetoglu et al., 2008). Some microtubule poisons have shown similar 
arrest in G2/M, but are markedly different from JG-03-14 in that they can activate 
p53 to execute apoptosis (Sayed et al, 2001).  Since the models tested with JG-
03-14 all show minimal induction of apoptosis in a system that contains wild-type 
p53, this is consistent with the idea that another mode of cell death (autophagy) 
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is occurring.  These findings could represent a unique advantage for the use of 
this drug in treatment of apoptosis resistant tumors. 
 
Cell Cycle Arrest in Response to JG-03-14 
In studies of drug effects on cell cycle distribution, we observed that the 
cells arrested primarily in the G2/M phase of the cell cycle. This is consistent with 
the effects of other microtubule depolymerizers (Azeddine et al., 1998; Quan et 
al., 2007).  These observations suggest that JG-03-14 failed to activate the G1 
cell cycle checkpoint; in fact, Western blotting indicated that JG-03-14 failed to 
induce either p53 or p21 (data not shown).  Although other microtubule poisons 
have been shown to arrest cells in G2/M and conclude with promotion of 
apoptosis as a means for cell killing (Zhu et al, 2010), this was clearly not the 
case for JG-03-14.    In JG-03-14 treated cells, autophagy does not appear to 
damage the nuclear contents based on DAPI staining, the TUNEL assay and 
non-induction of p53.  We therefore believe the population of cells arrested in 
G2/M phase may show continual depolymerizing activity to destroy cellular 
contents until the possibility of recovery has been bypassed. 
We also observed a hyperdiploid population after treatment of either 
B16F10 cells or HCT-116 cells with JG-03-14, likely due to the ability of cancer 
cells to undergo mitotic slippage out of the G2/M arrest and re-replicate their 
DNA in the absence of cytokinesis (Gross et al., 1995).    However, this response 
was unexpected in these p53 wild type cells, since endoreduplication is generally 
associated with the absence of functional p53 to induce G1 arrest and to sustain 
82 
 
 
 
 
arrest in G2 (Aylon et al, 2006); functional p53 generally promotes arrest in 
G0/G1 to prevent post-mitotic slippage (Stewart et al., 1999; Elhajouji et al, 
1998).  In fact, our previous studies showed that MDA-MB-231 mutant p53 breast 
tumor cells, but not p53 wild type MCF-7 cells, undergo endoreduplication (Arthur 
et al, 2007).  The ability of the wild type p53 HCT-116 colon cancer cells as well 
as the B16F10 melanoma cells to undergo mitotic slippage indicates that tumor 
cells can become polyploid even in cells with functional p53, presumably 
because checkpoint signaling downstream of p53 is attenuated. 
 
Absence of mitotic catastrophe in response to JG-03-14 
The fact that there was evidence of polyploidy indicated that the cells were 
attempting to undergo cytokinesis following the G2/M arrest. One possible 
outcome of aberrant mitosis would be mitotic catastrophe (Vakifahmetoglu et al., 
2008).  Cell death by mitotic catastrophe is characterized by the formation of 
nuclear envelopes around individual clusters of missegregated chromosomes. 
These are formed during the misguided or early entry into mitosis with aberrant 
cytokinesis. This then culminates with the accumulation of micronuclei and 
appears similar to necrotic cell death. Mitotic catastrophe remains to be fully 
defined biochemically but the mode of cell killing is also thought to be pre-stage 
to induction of apoptosis (Vakifahmetoglu et al., 2008). Caspase 3 and PARP 
cleavage as well as mitotic catastrophe have been seen in response to 
combretastatin (Vitale et al., 2006). Using Hoechst stain, we failed to detect 
evidence of mitotic catastrophe following treatment with JG-03-14. 
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Senescence and proliferative recovery 
In our studies, we showed that not only did the JG-03-14 compound arrest the 
cells in the G2/M stage, but that JG-03-14 also produced a massive amount of 
cell killing within this same population of cells possibly following the arrest.  After 
treatment, the cell population was monitored to determine if the surviving cells 
ultimately overcame the initial treatment and would regain proliferative capacity 
after the drug was removed.  Our studies in both cell lines indicated that 
proliferative recovery was entirely disrupted. The cells were incapable of 
replication as far out as 17 days after replacement of drug medium with drug-free 
medium.   
A large percent of the cells that were not killed entered into a senescent 
phase based on enlargement, flattening and lack of colony formation.  Beta-
galactosidase staining confirmed that this non-proliferating population was in fact 
senescent (Itahana et al., 2007; Arthur et al., 2007). Therefore, the variations in 
cell killing observed between the B16F10 cells and the HCT-116 may be due to 
the basal levels of autophagy (Tormo et al., 2009).  The basal levels of 
autophagy in the B16F10 melanoma cells seen may pre-stage the melanoma 
cells to enter into senescence instead of massive amounts of autophagic cell 
death seen in the HCT-116.  
Toxicity studies in cell culture and in vivo 
Since microtubule poisons such as taxol and combretastatin have a 
number of undesirable dose limiting toxicities, including peripheral neuropathy 
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and cardiotoxicity among others (Scuteri et al., 2006; Stevenson et al., 2003), it 
was of importance to assess the influence of JG-03-14 on heart cells and to 
perform behavioral studies relating to neuropathy as an indication of its potential 
to cause neuropathic injury.  In a preliminary dose response studies and using 
comparable doses of taxol and combretastatin, JG-03-14 appears to be least 
toxic of the three microtubule poisons. However, the relevance of this study to 
cardiac toxicity is somewhat questionable since the h9c2 cell line, unlike the 
heart, is a replicating model.  Another microtubule poison, colchicine, is not used 
in the clinic because of associated peripheral neuropathy and being a substrate 
for the p-glycoprotein pump (Kuncl et al., 1987).  This pump is one mechanism 
by which cancer cells can become resistant to chemotherapy and JG-03-14 has 
been shown not to be a substrate (Mooberry et al., 2007). Preliminary in vivo 
data also show there were no behavioral toxicity effects at doses of 100mg/kg 
and 200mg/kg.  These findings together with studies indicating minimal toxicity in 
vivo suggest that JG-03-14 could be an improvement over the current clinical 
therapies. 
 
Future Studies 
Our studies have confronted a number of problems when using 
pharmacological inhibitors of autophagy.  Chloroquine alone proved to be toxic in 
the B16F10 cells.  Other autophagic inhibitors that target the PI3-K pathway such 
as Wortmannin, LY-249002 and 3-methyl adenine prove to be toxic at 
concentrations necessary to show autophagic inhibition.  We therefore utilized 
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the late stage pharmacological inhibitors of autophagy at very low, non-toxic 
concentrations. An important study would be to use an inhibitor of caspase 
cleavage and possibly the induction of apoptosis. A pan-caspase inhibitor such 
as z-VAD in combination with JG-03-14 and a low dose autophagic inhibitor may 
divulge some mechanisms of cell response and possibly alter sensitivity (Yu et 
al., 2003).  In order to fully understand the process, we also want to silence 
genes (atg’s) as well as Beclin-1 (Suzuki et al., 2007; Yue et al., 2003).  This 
approach would determine the reliance of JG-03-14 on autophagy proteins for 
cell killing.  Since JG-03-14 has also been shown to induce apoptosis in other 
cell lines, the mechanism of cell killing may be cell type dependent (Arthur et al., 
2007; Mooberry et al., 2007).  
Knowledge of the precise signaling pathways for autophagic death 
induced by JG-03-14 remain to be defined, with a focus on mTOR and ER stress 
signaling. The literature suggests that autophagy could be a consequence of 
selective protein degradation, specifically catalase degradation causing an 
accumulation of ROS or degradation of other essential proteins that would 
eventually kill the cells (Yu et al., 2006; Onodera and Ohsumi, 2004).  In concert 
with further defining the mechanism of action of JG-03-14, we would also like to 
see if it is as efficacious in vivo as it is in vitro.  This would help define if the 
effects in cell culture are translational and could be applicable to the clinic. It 
would be of particular interest to test JG-03-14 in an immunocompetent mouse to 
see if some of the autophagic and senescent effects were to be cleared by the 
immune system. 
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Overview 
   
In summary, these studies lead to a number of conclusions. Colchicine is 
not used in the clinic because it has been shown to be a substrate for the p-
glycoprotein MDR pump as well as the glutathione S-transferase found in 
resistant cells (Ruiz-Gomez et al, 2000).  Colchicine has also been shown to 
suppress bone marrow function (Liu et al, 2008; Harris et al, 2000) and to be 
highly toxic. In contrast, JG-03-14 had been determined not to be a substrate for 
the p-glycoprotein pump and to be relatively non-toxic (Mooberry et al, 2007). 
   
Different microtubule targeting agents can cause either a G1 or G2 arrest, 
and the arrest may be p53-dependent or p53 independent.  The fact that JG-03-
14 induced a G2 arrest and there was no induction of p53 suggests that JG-03-
14 may be less reliant on p53.  This is significant in that cancers that acquire 
resistance via evasion of the p53-dependent mechanism may be sensitive to the 
alternative mechanism of cell cycle arrest that could ultimately lead to an 
alternative death signal.  Since adjuvant radiotherapy is often used in preventing 
colon cancer recurrence, a G2/M block induced by JG-03-14 could stage the 
colon cancer cells for radiosensitization (Zheng, 2008; Jorgensen et al, 2007).  
   
The results presented above have potentially important implications for 
JG-03-14 as a clinically effective agent due to its ability to promote autophagy.  
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By targeting autophagic induction of tumor regression, JG-03-14 may be able to 
bypass colon cancer and melanoma’s high metastatic rate which typically 
accompanies resistance to apoptosis.   
   
Drugs that target microtubules are important in cancer therapeutics, some 
of which are among the most effective in treating childhood and adult tumors.  
Though drugs such as combretastatin A-4 and 2ME2 bind to the same site on 
tubulin, they have different effects on tumor vasculature.  2ME2 has anti-
angiogenic actions while combretastatin A-4 has anti-vascular activities that lead 
to a rapid collapse in tumor vasculature (Mooberry et al., 2003; Griggs et al.,  
2001).  The ability of JG-03-14 to bind to tubulin and its action as a 
depolymerizer suggest its potential effects on tumor vasculature The maturation 
of angioblasts into endothelial cells is crucial for vascular tubule formation (Tozer 
et al, 1999).  JG-03-14 at 100 nM concentration was able to inhibit endothelial 
cells tube formation, attachment, and migration, which indicates that JG-03-14 
may have potential as a chemotherapeutic drug for cancer (Dalyot-Herman et al, 
2009).  
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